Spiden: Real-time continuous monitoring
Founded in 2017 by Leo Grünstein, Spiden develops an optical AI based technology to analyse blood, urine and other body fluids through real-time, continuous monitoring, thereby helping to increase safety and optimise treatment of critical and high-risk patients.
Spiden’s mission is to develop medical technologies that will improve the lives of millions of people by continuously monitoring health indicators which will support timely and individualised diagnostics. The company is looking to take a revolutionary leap forward in the well-being of humanity through biomarker analysis.
The startup uses advanced spectral techniques and data analysis, focusing on the patients blood. This unique combination of advanced spectral techniques with state-of-the-art data analysis is a novel approach for technology miniaturisation which allows the startup to measure biomarkers and drugs in real time in blood.
For more information, visit-